216 related articles for article (PubMed ID: 35794497)
1. Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.
Khan MF; Ansari WA; Ahamad T; Khan MA; Khan ZA; Sarfraz A; Khan MA
J Mol Model; 2022 Jul; 28(8):212. PubMed ID: 35794497
[TBL] [Abstract][Full Text] [Related]
2. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
3. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Basu A; Sarkar A; Maulik U
Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
6. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
Rui L; Haonan L; Wanyi C
Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
[TBL] [Abstract][Full Text] [Related]
7.
Br B; Damle H; Ganju S; Damle L
F1000Res; 2020; 9():663. PubMed ID: 32765844
[No Abstract] [Full Text] [Related]
8.
Tiwari V
Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878881
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.
Alazmi M; Motwalli O
J Mol Model; 2020 Nov; 26(12):338. PubMed ID: 33175236
[TBL] [Abstract][Full Text] [Related]
10. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
11. Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.
Li C; Zhou H; Guo L; Xie D; He H; Zhang H; Liu Y; Peng L; Zheng L; Lu W; Mei Y; Liu Z; Huang J; Wang M; Shu D; Ding L; Lang Y; Luo F; Wang J; Huang B; Huang P; Gao S; Chen J; Qian CN
J Transl Med; 2022 Jul; 20(1):314. PubMed ID: 35836239
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y
PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431
[TBL] [Abstract][Full Text] [Related]
13. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
14. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
[TBL] [Abstract][Full Text] [Related]
15. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.
Jena AB; Kanungo N; Nayak V; Chainy GBN; Dandapat J
Sci Rep; 2021 Jan; 11(1):2043. PubMed ID: 33479401
[TBL] [Abstract][Full Text] [Related]
16. In Silico Molecular Dynamics of Griseofulvin and Its Derivatives Revealed Potential Therapeutic Applications for COVID-19.
Aris P; Mohamadzadeh M; Wei Y; Xia X
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805893
[TBL] [Abstract][Full Text] [Related]
17. Interaction of Bioactive Compounds of Moringa oleifera Leaves with SARS-CoV-2 Proteins to Combat COVID-19 Pathogenesis: a Phytochemical and In Silico Analysis.
Siddiqui S; Upadhyay S; Ahmad R; Barkat MA; Jamal A; Alothaim AS; Hassan MZ; Rahman MA; Arshad M; Ahamad T; Khan MF; Shankar H; Ali M; Kaleem S; Ahmad J
Appl Biochem Biotechnol; 2022 Dec; 194(12):5918-5944. PubMed ID: 35838886
[TBL] [Abstract][Full Text] [Related]
18. [Role of ACE2 in COVID-19].
Imai Y
Nihon Yakurigaku Zasshi; 2022; 157(2):115-118. PubMed ID: 35228442
[TBL] [Abstract][Full Text] [Related]
19. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
20. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
